Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBB 1 Combination Vaccine in Healthy People
NCT06548139Phase 2Not yet recruiting
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CBB1 in rabies, sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Rabies Virus Neutralizing Antibody Activity at 7 Days. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
CBB1
03
Conditions
rabies
Beyond the preview
Go deeper on NCT06548139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548139.